Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Receives European Medicines Agency Approval To Initiate A Phase Ib Study Of Iadademstat In Sickle Cell Disease

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    25/08/2025 13:27
    Aug 25 (Reuters) - Oryzon Genomics SA ORY.MC:

ORYZON RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE A PHASE IB STUDY OF IADADEMSTAT IN SICKLE CELL DISEASE

Source text: ID:nGNX9zBn71

Further company coverage: ORY.MC

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ORYZON Genomics SA

    See all news